AstraZeneca in talks to produce COVID-19 vaccine for feds at Catalent site in Maryland: report

With production nixed at a Baltimore plant—and its shot’s role in the U.S. vaccination scheme uncertain—AstraZeneca may turn to one of its established pandemic manufacturing partners to crank out doses for the feds.